No apparent effect of naproxen on CSF markers of innate immune activation

The PREVENT-AD Research Group

Research output: Contribution to journalArticlepeer-review


We studied 78 participants having a parental or multiple-sibling history of Alzheimer’s disease (AD) in a two-year randomized placebo-controlled trial of naproxen 220 mg b.i.d. for mitigation of early AD pathogenesis. Naproxen was detected in cerebrospinal fluid at concentrations ~100 times lower than in plasma, but produced negligible change in immune markers. The repeated lack of benefit in AD prevention trials using naproxen and related drugs may reflect limited CNS permeability, lack of expected drug effects, or both. These findings suggest reconsideration of implications from results of AD prevention trials using anti-inflammatory drugs.

Original languageEnglish (US)
Pages (from-to)1127-1133
Number of pages7
JournalAnnals of Clinical and Translational Neurology
Issue number6
StatePublished - Jun 1 2019

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'No apparent effect of naproxen on CSF markers of innate immune activation'. Together they form a unique fingerprint.

Cite this